Company Filing History:
Years Active: 2025
Title: Jinxiong Su: Innovator in BTK Inhibitor Development
Introduction
Jinxiong Su is a notable inventor based in Changzhou, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of BTK inhibitors. With a total of two patents to his name, Su's work is recognized for its innovative approaches to drug formulation.
Latest Patents
Su's latest patents focus on processes and intermediates for preparing a BTK inhibitor. One of the disclosed processes involves the preparation of certain intermediates, specifically a compound of formula (I) or a pharmaceutically acceptable salt thereof, in an enantioenriched form. This intermediate and the associated processes are crucial for the preparation of BTK inhibitors, such as ibrutinib. Another patent similarly outlines a process for preparing a compound of formula (I), where R, R, and X are defined in the description, emphasizing the utility of these intermediates in BTK inhibitor development.
Career Highlights
Jinxiong Su is currently associated with Janssen Pharmaceutica NV, a leading company in the pharmaceutical industry. His work at Janssen has allowed him to focus on innovative drug development, contributing to advancements in therapeutic options for various diseases.
Collaborations
Su has collaborated with notable colleagues in his field, including Philip James Pye and Andras Horvath. These collaborations have fostered a productive environment for research and development, enhancing the impact of their collective work.
Conclusion
Jinxiong Su's contributions to the field of pharmaceuticals, particularly in the development of BTK inhibitors, highlight his innovative spirit and dedication to advancing medical science. His patents reflect a commitment to improving therapeutic options for patients, showcasing the importance of collaboration and research in the pharmaceutical industry.